Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective

Crit Rev Oncol Hematol. 2021 Apr:160:103300. doi: 10.1016/j.critrevonc.2021.103300. Epub 2021 Mar 17.


Since their discovery, relevant efforts have been made to optimize the detection approaches to EGFR mutations as well as the clinical management of EGFR-mutated NSCLC. The recent shift from single gene testing to novel comprehensive detection platforms along with the development of new generation tyrosine kinase inhibitors, targeting both common and uncommon EGFR-mutations, is leading to a progressive increase in the number of patients who may benefit from targeted approaches, with subsequent impact on their long-term survival and quality of life. However, a prompt and adequate implementation of the most recent diagnostic and treatment advances in the routine practice often remains critical to be specifically addressed. In this review we provide a complete and updated overview of the different detection platforms and therapeutic options currently available for the clinical management of advanced EGFR-positive NSCLC, summarizing scientific evidence and describing molecular testing as well as treatment practice in the real-word scenario.

Keywords: Common mutations; EGFR; Molecular testing; Non-small cell lung cancer; Tyrosine kinase inhibitors; Uncommon mutations.

Publication types

  • Review

MeSH terms

  • ErbB Receptors / genetics
  • Humans
  • Italy
  • Lung Neoplasms* / diagnosis
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use
  • Quality of Life*


  • Protein Kinase Inhibitors
  • EGFR protein, human
  • ErbB Receptors